Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
about
Intermittent preventive treatment of malaria in pregnant women and infants: making best use of the available evidenceAdvances and challenges in malaria vaccine developmentTransgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccinesVaccines for preventing malaria (pre-erythrocytic)Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidateEfficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of ageMaking practical markets for vaccines. Why I decided that the Center for Global Development Report, Making Markets for Vaccines, offers poor advice to government and foundation leadersPlasmodium species mixed infections in two areas of Manhiça district, MozambiqueTargeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial ResistanceMalaria vaccine: a future hope to curtail the global malaria burdenVaccines for malaria: how close are we?Broadening the horizons for yellow feverMalaria: progress, perils, and prospects for eradicationYoung lives lost as B cells falter: what we are learning about antibody responses in malaria.Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious DiseasesA phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in KenyaA plant-derived morphinan as a novel lead compound active against malaria liver stagesGenistein-supplemented diet decreases malaria liver infection in mice and constitutes a potential prophylactic strategyReducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategiesCost-effectiveness of intermittent preventive treatment of malaria in pregnancy in southern MozambiqueA head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trialVaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of PlasmodiumThe role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trialT cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian childrenA viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activityInduction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & childrenProtective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cellsCircumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malariaSafety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenSafety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trialImmunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium bergheiEstimating Plasmodium falciparum transmission rates in low-endemic settings using a combination of community prevalence and health facility dataEfficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data.Modelling recurrent events: comparison of statistical models with continuous and discontinuous risk intervals on recurrent malaria episodes dataImpact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.Sequence variation in the T-cell epitopes of the Plasmodium falciparum circumsporozoite protein among field isolates is temporally stable: a 5-year longitudinal study in southern Vietnam.RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection.Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children.
P2860
Q21032450-7D4556A1-1E45-4C46-82E2-F1D99D60B84DQ21032463-EC11C56C-D918-4558-B74D-7051B60E6031Q21032495-7E856162-4FB8-437E-B9A5-B9E9A0D7D25BQ24244317-B9892E5A-B569-4D95-913F-C66A0332B6C9Q24648408-DBAD5DF2-2E17-42CC-B36D-BEBBBFFE39D9Q24658073-FD1C2449-27D5-4A23-A384-A4461875A752Q24812901-47E21CBF-45F0-4D83-8C71-69A64A266567Q24816067-12C15D59-1618-4EAB-99BE-FE1D8CCD0CCBQ26864290-EDDCB04A-80F1-485A-9505-E794DCF90E27Q26996425-68D90452-568C-4892-925F-908DAE6A564DQ27024344-6E7403AB-D6B0-4AD2-9FD5-C2AD7B1EDE9AQ27485206-53279917-D5AE-410E-8F61-25246B18109FQ27485634-3923A70F-7953-4031-8F3D-0575A17F7E7DQ27687235-F9D3F8E9-766E-4021-8583-ADD8C785EC81Q28383084-CA39C0E0-4608-4A58-8742-E22F078FB9C2Q28469062-8213D9A8-25C0-471C-831E-5989DE788B2AQ28469086-3234D93A-C3EC-4B16-8597-5B625B7D34CFQ28473154-C742352D-1D43-4A7E-8161-21CDD0898E8AQ28475084-C7C041C6-B6F6-4F4E-9579-2644373A174EQ28475795-60D58752-750D-4E8A-9DDA-1D3D89F8AD8DQ28477853-F863618E-3DB2-49AC-8F21-A35631E15745Q28730541-2AA84BD3-7258-4E9B-B70F-71773FA70A95Q28731458-8A3D4FE5-64D2-49B9-8C82-E952E9AC3173Q28740701-4F30ECC9-DFF5-4FEB-AEE0-243632C627A2Q28740771-AC9C6AD6-6644-4278-AA5B-589936E08ACEQ28741242-28511DEE-D295-4976-A341-A2F33314BF75Q28742277-A1A2CCC5-C479-45E5-95A6-0E08983369D4Q28742596-357F4FC3-B144-4467-B3A6-EABEA3F11F55Q28744170-29784737-5EC1-4E1E-8588-CF24568EC5A7Q28744573-7D2971A3-A525-40BD-9500-329172C95E99Q28748565-390C3018-4178-4B07-A904-475C50100ECAQ28749621-9C79524B-717E-4B86-8B69-1E564B7CAF21Q30000840-B263EB77-F0E3-4D7C-A519-AEF5E73485CAQ30596414-17D3FEFC-59B1-46AD-A94C-54C0639DB86DQ30662529-63876CB6-FFBF-4A8F-86AB-E936FA7E102EQ30839403-E14132CE-0B2B-4AEE-823B-9F0940FBBF06Q30895708-26F1C6D4-B0A0-4D32-8C46-B04BEA051A8CQ33239047-5E0E64E0-3BD3-4769-9327-52CE91245C43Q33251913-9689F9C5-2F0B-4911-A936-43D10AE9AE1AQ33264521-B9EB9106-FF1C-4FE0-B721-51585A7AA69D
P2860
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Efficacy of the RTS,S/AS02A va ...... : randomised controlled trial.
@ast
Efficacy of the RTS,S/AS02A va ...... : randomised controlled trial.
@en
Efficacy of the RTS,S/AS02A va ...... : randomised controlled trial.
@nl
type
label
Efficacy of the RTS,S/AS02A va ...... : randomised controlled trial.
@ast
Efficacy of the RTS,S/AS02A va ...... : randomised controlled trial.
@en
Efficacy of the RTS,S/AS02A va ...... : randomised controlled trial.
@nl
prefLabel
Efficacy of the RTS,S/AS02A va ...... : randomised controlled trial.
@ast
Efficacy of the RTS,S/AS02A va ...... : randomised controlled trial.
@en
Efficacy of the RTS,S/AS02A va ...... : randomised controlled trial.
@nl
P2093
P50
P1433
P1476
Efficacy of the RTS,S/AS02A va ...... : randomised controlled trial.
@en
P2093
Amanda Leach
Bart Spiessens
Caterina Guinovart
Eusebio Macete
Filip Dubovsky
Jessica Milman
Marc Ceuppens
Margarita M Navia
Marie-Ange Demoitié
P304
P356
10.1016/S0140-6736(04)17223-1
P407
P50
P577
2004-10-01T00:00:00Z